JP2019530728A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019530728A5 JP2019530728A5 JP2019520627A JP2019520627A JP2019530728A5 JP 2019530728 A5 JP2019530728 A5 JP 2019530728A5 JP 2019520627 A JP2019520627 A JP 2019520627A JP 2019520627 A JP2019520627 A JP 2019520627A JP 2019530728 A5 JP2019530728 A5 JP 2019530728A5
- Authority
- JP
- Japan
- Prior art keywords
- recipient
- transplantation
- antibody
- composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022020361A JP2022051954A (ja) | 2016-10-12 | 2022-02-14 | 感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662407167P | 2016-10-12 | 2016-10-12 | |
| US62/407,167 | 2016-10-12 | ||
| PCT/US2017/056268 WO2018071624A1 (en) | 2016-10-12 | 2017-10-12 | Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022020361A Division JP2022051954A (ja) | 2016-10-12 | 2022-02-14 | 感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019530728A JP2019530728A (ja) | 2019-10-24 |
| JP2019530728A5 true JP2019530728A5 (enExample) | 2020-11-12 |
| JP7256741B2 JP7256741B2 (ja) | 2023-04-12 |
Family
ID=60320981
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520627A Active JP7256741B2 (ja) | 2016-10-12 | 2017-10-12 | 感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性 |
| JP2022020361A Pending JP2022051954A (ja) | 2016-10-12 | 2022-02-14 | 感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022020361A Pending JP2022051954A (ja) | 2016-10-12 | 2022-02-14 | 感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20190276524A1 (enExample) |
| EP (1) | EP3526250A1 (enExample) |
| JP (2) | JP7256741B2 (enExample) |
| WO (1) | WO2018071624A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ711451A (en) | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| AU2017269839A1 (en) | 2016-05-27 | 2018-11-22 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis |
| WO2017218515A1 (en) | 2016-06-14 | 2017-12-21 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibodies and uses thereof |
| ES2888904T3 (es) | 2016-10-19 | 2022-01-10 | Alexion Pharma Inc | Un método de cuantificación de C5a sin unir en una muestra |
| WO2018195034A1 (en) * | 2017-04-19 | 2018-10-25 | Alexion Pharmaceuticals, Inc. | Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant |
| BR112020001703B1 (pt) | 2017-07-27 | 2024-01-02 | Alexion Pharmaceuticals, Inc | Solução aquosa estável compreendendo um anticorpo anti-c5, método para produção desta solução, uso da mesma para tratar uma condição associada ao complemento e kit terapêutico compreendendo a mesma |
| EP3700928A1 (en) | 2017-10-26 | 2020-09-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) |
| MX2020006113A (es) | 2017-12-13 | 2020-08-24 | Regeneron Pharma | Combinaciones de anticuerpos anti-c5 y usos de las mismas. |
| US12404320B2 (en) | 2018-05-31 | 2025-09-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients |
| JP7577542B2 (ja) | 2018-06-04 | 2024-11-05 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与 |
| EP3814373A1 (en) | 2018-06-28 | 2021-05-05 | Alexion Pharmaceuticals, Inc. | Methods of producing anti-c5 antibodies |
| MX2021004994A (es) | 2018-10-30 | 2021-06-15 | Alexion Pharma Inc | Dosificacion subcutanea y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (pnh). |
| CN116194478A (zh) | 2020-06-24 | 2023-05-30 | 阿雷克森制药公司 | 皮下（sc）施用抗c5抗体治疗补体相关病症 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1621554E (pt) | 1992-08-21 | 2009-07-13 | Univ Bruxelles | Imunoglobtainas desprovidas de cadeias leves |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US8178098B2 (en) | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
| WO2010011697A1 (en) * | 2008-07-21 | 2010-01-28 | Immunomedics Inc. | Structural variants of antibodies for improved therapeutic characteristics |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| NZ711451A (en) * | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| CN109310760A (zh) * | 2016-06-07 | 2019-02-05 | 诺华股份有限公司 | 抗c5抗体给药方案 |
-
2017
- 2017-10-12 JP JP2019520627A patent/JP7256741B2/ja active Active
- 2017-10-12 US US16/340,453 patent/US20190276524A1/en not_active Abandoned
- 2017-10-12 EP EP17797792.3A patent/EP3526250A1/en not_active Ceased
- 2017-10-12 WO PCT/US2017/056268 patent/WO2018071624A1/en not_active Ceased
-
2022
- 2022-02-14 JP JP2022020361A patent/JP2022051954A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10647770B2 (en) | Therapeutic agent for autoimmune diseases comprising PD-1 agonist | |
| EP2430051B1 (en) | Compositions containing antibodies for treating cd5+ hla-dr+ b or t cell related diseases | |
| CN1344275A (zh) | 用淀粉样蛋白抗体除去淀粉样蛋白的方法 | |
| JP2011006449A (ja) | 中間および高グレードの非ホジキンリンパ腫の抗−ｃｄ２０抗体による治療 | |
| FI3556774T3 (fi) | Anti-cd40-vasta-aineita ja niiden käyttötapoja | |
| JP5688734B2 (ja) | 移植片対腫瘍効果を保存した免疫学的再構築促進剤または感染症予防剤 | |
| JP2025106512A (ja) | 調節性ｔ細胞及びその使用 | |
| JP2016531910A (ja) | 移植前の臓器への補体阻害剤の投与による移植拒絶の処置 | |
| Balfour et al. | Use of rituximab to decrease panel-reactive antibodies | |
| CN102159243A (zh) | 用于改良的治疗特征的抗体的结构变体 | |
| JP2014505056A5 (enExample) | ||
| JP2025502095A5 (enExample) | ||
| WO2014020922A1 (ja) | 移植片対宿主病などの造血幹細胞移植に伴う疾患を治療することのできる抗体およびその機能断片並びにこれらを含んでなる医薬組成物 | |
| CA1328808C (fr) | Agent actif et medicament en contenant destines a prevenir ou a combattre le rejet de greffe d'organe chez l'homme | |
| JP2021514368A (ja) | Ａｌｌｏ−ＨＣＴを受けた患者の血液悪性腫瘍の治療に使用するためのＧＭ−ＣＳＦまたはＧＭ−ＣＳＦ受容体のリガンド | |
| KR102693802B1 (ko) | 변형된 이식편의 사전 사용에 의한 이식편 거부의 방지 | |
| JP6942356B2 (ja) | 制御性ｔ細胞の活性化剤及びその使用 | |
| Yasuda et al. | The changes in treatment strategies in ABOi living donor liver transplantation for acute liver failure | |
| Calne | A brief history of clinical organ transplantation | |
| KR101694554B1 (ko) | 자연살해세포 억제제 및 간엽줄기세포를 유효성분으로 포함하는 이식편대숙주질환의 예방 또는 치료를 위한 세포치료제 조성물 | |
| Amante et al. | Management of highly sensitized patients: capitol medical center experience | |
| AU2005211669C1 (en) | Treatment of intermediate- and high-grade non-Hodgkins lymphoma with anti-CD20 antibody | |
| Singh et al. | Plasmapheresis vs Immunoadsorption vs Combined Plasmapheresis and Immunoadsorption Therapy: A Comparative Analysis of Desensitization Efficacy in ABO Incompatible Renal Transplant with High Baseline Titer | |
| Gupta et al. | Management of steroid-resistant acute rejection in renal transplantation | |
| CA2161797A1 (en) | Xenograft thymus |